India’s life sciences industry is becoming more than a manufacturing story. Pharmaceutical research, contract development, biotechnology, clinical development and advanced biological products are creating new opportunities for companies that want to participate in the future of global healthcare.
Recent quarterly results from Indian life sciences companies offer a useful indication of the sector’s momentum. Hyderabad-based Sai Life Sciences reported 23% year-on-year revenue growth for the September quarter of FY2026–27, according to industry reporting on November 9. Its EBITDA increased 20% to ₹187 crore, while its EBITDA margin remained at 28%.
The results are important because Sai Life Sciences operates in the contract research, development and manufacturing organisation segment, commonly known as CRDMO. These companies support pharmaceutical and biotechnology businesses with research, development and manufacturing services.
The global pharmaceutical industry increasingly relies on specialised partners to help develop complex medicines. Drug discovery, laboratory testing, process development and manufacturing can require significant technical expertise and infrastructure. CRDMOs provide these capabilities to companies that may not want to build every facility internally.
India has an opportunity to strengthen its position in this market. The country already has an established pharmaceutical manufacturing ecosystem, a large pool of scientific professionals and experience in producing medicines for international markets. The next step is to expand capabilities in more research-intensive and complex areas.
Other recent financial results also demonstrate activity across the sector. Cohance Lifesciences reported sequential revenue growth of 12.9% and indicated expectations of stronger performance in the second half of FY2026–27. Abbott India’s September-quarter EBITDA rose to ₹568 crore, while Gland Pharma reported a 58% increase in quarterly profit, supported by higher revenue.
These results should not be interpreted as evidence that every company or segment is growing equally. Performance differs according to product portfolios, international markets, research pipelines, manufacturing costs and business strategy.
Nevertheless, they illustrate the breadth of India’s life sciences ecosystem. The sector includes pharmaceutical manufacturers, biologics companies, laboratory service providers, research organisations, medical technology businesses and specialised suppliers.
Artificial intelligence is also beginning to influence scientific research. AI-assisted drug discovery and data analysis may help researchers identify promising molecules, study biological systems and prioritise experiments. However, laboratory validation and clinical testing remain essential. A promising computer-generated prediction is not the same as a proven medicine.
The industry also faces challenges. Research requires sustained investment, specialised talent, strong intellectual-property protection and strict quality standards. Companies working with international clients must meet demanding regulatory expectations.
For investors and entrepreneurs, the opportunity lies in building expertise rather than simply increasing production volumes. Advanced research services, complex generics, biologics and specialised manufacturing could help Indian companies move further up the global value chain.
The future of life sciences will depend on the ability to combine scientific discovery with reliable execution. India’s established strengths provide a foundation, but sustained investment in research and innovation will determine how far the industry can progress.
The next major healthcare breakthrough may emerge from a global collaboration. Indian research and manufacturing capabilities could play an increasingly important role in making that breakthrough possible.
